Induction therapy for stage IIIA (N2) lung cancer

One of the major goals of the International Staging System for Lung Cancer, first introduced in 1986 and subsequently revised in 1997, was the separation of patients into potentially resectable and unresectable categories. This dividing line was set between stage IIIA and stage IIIB disease with contralateral lymph node metastases or local involvement of unresectable or marginally resectable structures defining the limits of surgical treatment. treatment. The advent of modern cancer therapy with multimodality approaches including surgery, chemotherapy, and radiation therapy has raised significant questions that are still not completely resolved as to the best approach for patients with potentially resectable stage IIIA (N2) disease at presentation. © 2007 Springer-Verlag London Limited.

Duke Scholars

Author David Harold Harpole Jr. Surgery, Cardiovascular and Thoracic Surgery